Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Improving inpatient GHB detoxification with baclofen
2023-506167-34-02Phase 2Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of baclofen in gamma-hydroxybutyrate use disorder (GHBUD), sponsored by Radboud University Medical Center. Primary endpoint: Pharmaceutical GHB dosage at the end of the titration phase during inpatient detoxification. Planned start Dec 2023; status: authorised.
02
Drugs
baclofen
03
Conditions
gamma-hydroxybutyrate use disorder (GHBUD)
Beyond the preview
Go deeper on 2023-506167-34-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506167-34-02.